[Below are the Areas of Interest for consideration for GSK’s Assets:]

[For belantamab mafodotin these include (updated November 2024):]
Combination Therapies:
• Belamaf in combination with mezigdomide (plus other CeLMoDs) in the RRMM & FL maintenance setting.
• Belamaf in combination with non-BCMA–targeting T-cell engagers, particularly those specific to GPRC5D (plus Pd or other SoC), FcRH5.
• Induction with BCMA-targeting T-cell engagers followed by low-dose belamaf maintenance therapy.
• Agents with scientific rationale including combinations that address areas of high unmet need (high risk, early relapse, etc.)

Patient Populations:
• Clinical use and outcomes following belamaf treatment in minority populations, including those of African American descent.
• Belamaf efficacy and safety in subpopulations of interest not addressed through existing studies.

Additional Therapeutic Targets:
• BCMA expressing malignancies (amyloidosis, waldenstrom, etc.).
• Non-malignant conditions where plasma cells play a key component to disease (e.g. Lupus etc.)

Sequencing:
• Use of belamaf (plus SoC) before treatment with other BCMA-targeting therapies (e.g., crossover for toxicity).
• Membrane-bound BCMA expression with BCMA-targeted therapies (translational elements for incorporation into interventional studies)
- At baseline and time of progression with BCMA-targeted therapies
- At the time of initiation of new therapy for patients after coming off prior BCMA-targeted therapy (by dose if applicable)

Mechanism of Action:
• Deeper understanding of Immune Cell Death (ICD).

Ocular Management Safety monitoring:
• Use of visual acuity or symptoms as a surrogate; safety assessment according to symptom-based dose modification approach.
• Physician assessments guiding alternative approaches to dosing decisions.

Supportive care for management of ocular AEs:
• Definition of clinically meaningful change in visual acuity (Snellen 20/50) and its differentiation from other ocular symptoms (e.g., dryness, itching, and pain).
• Mechanisms underpinning belamaf-associated ocular events.


[Momelotinib Areas of Interest (updated February 2025):]
Myelofibrosis (MF) Combinations:
Combination of MMB with agents (1L or as 'add-on') with potential for disease modification, not limited to:
• Anti-HJV (e.g., DISC-0974)
• BET inhibitors
• Anti-CALR therapies
• LSD1 inhibitors (e.g. bomedemstat)
• MDM2 inhibitors (e.g., Navtemadlin)
• PIM1 inhibitors (e.g., TP-3654)
• Telomerase inhibitors (e.g., Imetelstat)
• TGFb modulators (e.g., KER-050)
• XPO1 inhibitors (e.g., Selinexor)

Note: Proposals to address other hematologic malignancies may be considered for those with extraordinary scientific rationale (case-by-case)

• Chronic graft-vs-host-disease

[For Dostarlimab these include (updated November 2024; pending further updates soon):]
Investigation of dostarlimab in Gyn-Onc, Head and Neck, and Colorectal/GI indications that can support current registrational studies through meaningful evidence generation.

[For niraparib, these include (updated November 2024):]
Ovarian Cancer
• Investigation of PARPi monotherapy strategies for identifying the appropriate patient population that could benefit from PARPi monotherapy.
• Optimizing patient experience and mitigation of adverse effects.

Glioblastoma
• Studies exploring treatment strategies in methylated patient population.